C.R. Bard Buys FlowCardia, Inc. For $80 Million

P.E. Hub -- C. R. Bard Inc. (NYSE: BCR) has acquired FlowCardia Inc., a Sunnyvale, Calif.-based developer of endovascular devices for coronary and peripheral chronic total occlusion (CTO) recanalization, according to VentureWire. The deal is worth around $80 million.